| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.2 | 0.0006 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0007 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0007 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0008 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0009 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |